Targeting nuclear bile acid receptors for liver disease

Digestive Diseases

Volumn 29, Issue 1, 2011, Pages 98-102

  Trauner, Michael ^a   Baghdasaryan, Anna ^b   Claudel, Thierry ^b   Fickert, Peter ^b   Halilbasic, Emina ^a   Moustafa, Tarek ^b   Zollner, Gernot ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bile acids; Liver disease; Nuclear receptors

Indexed keywords

BILE ACID; GLUCOCORTICOID RECEPTOR; LIVER X RECEPTOR; NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; TRANSCRIPTION FACTOR; VITAMIN D RECEPTOR;

CHOLESTASIS; CONFERENCE PAPER; FATTY LIVER; FIBROGENESIS; GLUCOSE METABOLISM; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER DISEASE; LIVER REGENERATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; VIRUS REPLICATION;

ANIMALS; BILE ACIDS AND SALTS; CHOLESTASIS; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIVER DISEASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 79959508374     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000324141     Document Type: Conference Paper

References (19)

1. Karpen SJ: Nuclear receptor regulation of hepatic function. J Hepatol 2002; 36: 832-850. (Pubitemid 35177416)
2. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B: Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-191.
3. Wagner M, Zollner G, Trauner M: Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin Liver Dis 2010; 30: 160-177.
4. Boyer JL: New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol 2007; 46:365-371. (Pubitemid 46201718)
5. Zollner G, Trauner M: Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009; 156:7-27.
6. Arenas F, Hervias I, Uriz M, Joplin R, Prieto J, Medina JF: Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 2008; 118: 695-709. (Pubitemid 351206558)
7. Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I, Oude Elferink R P, Prieto J, Medina JF: Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008; 134: 1482 - 1493. (Pubitemid 351626951)
8. Keitel V, Kubitz R, Häussinger D: Endocrine and paracrine role of bile acids. World J Gastroenterol 2008; 14: 5620-5629.
9. Claudel T, Trauner M: Bile acids and their receptors; in Dufour J, Clavien P (eds): Signaling Pathways in Liver Diseases. Berlin, Springer Scientific Publishers, 2009.
10. Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Halsegger S, Adorini L, Strazzabosco M, Fickert P, Trauner M: Therapeutic targeting of nuclear and membrane bile acid receptors in a mouse model of chronic cholestasis. Hepatology 2010; 52:724.
11. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M: 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-481. (Pubitemid 43202044)
12. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P: Bile acids as regulatory molecules. J Lipid Res 2009; 50:1509-1520.
13. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K: Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7:678-693.
14. Claudel T, Staels B, Kuipers F: The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25:2020-2030.
15. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M: Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010; 28:220-224.
16. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS: Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313:1137-1140. (Pubitemid 44300242)
17. Wagner M, Zollner G, Trauner M: Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. Hepatology 2008; 48: 1383-1386.
18. Karpen SJ, Trauner M: The new therapeutic frontier - nuclear receptors and the liver. J Hepatol 2010; 52:455-462.
19. Paumgartner G, Beuers U: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36:525-531. (Pubitemid 34977162)